SVAのチャート
SVAの企業情報
| symbol | SVA |
|---|---|
| 会社名 | Sinovac Biotech Ltd （シノバック・バイオテック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 シノバク・バイオテク(Sinovac Biotech Ltd.)は中国の統合型バイオ医薬品会社であり、伝染病予防のためのワクチンの研究、開発、製造及び商業化に注力する。同社はA型肝炎、B型肝炎及びインフルエンザ・ウイルス、H5N1とH1N1パンデミックインフルエンザや流行性耳下腺炎、並びに動物の狂犬病ワクチンに対応するワクチンにより構成される製品ポートフォリオを開発する。同社の製品パイプラインには、ロタウイルス、前臨床開発中である人間の狂犬病に対するヒトワクチンを含む。同社は特にアンメット?メディカル?ニーズを持つ感染症向けのワクチンを開発、生産と販売する。同社は中国において、肺炎球菌、ロタウイルス、狂犬病、水痘、風疹向けのEV71ワクチンとヒト用ワクチンの前臨床・臨床開発段階のワクチン候補により構成されるパイプラインを有する。 シノバック・バイオテックは、中国のバイオ医薬品会社。子会社を通じ、インフルエンザ、A 型肝炎、流行性耳下腺炎(おたふく風邪)、狂犬病などのワクチンに関する研究開発、生産、販売を手掛ける。中国をはじめ、モンゴル、ネパ―ル、フィリピン、メキシコなどで製品を販売。本社は北京。 Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide ('PPV'), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China. |
| 本社所在地 | No. 39 Shangdi Xi Road Haidian District Beijing 100085 CHN |
| 代表者氏名 | WeiDong Yin WeiDong Yin |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Secretary |
| 電話番号 | +86 10-8289-0088 |
| 設立年月日 | 36220 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 835人 |
| url | www.sinovac.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sva |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 50.21400 |
| 終値（lastsale） | 7.6238 |
| 時価総額（marketcap） | 526666291.8918 |
| 時価総額 | 時価総額（百万ドル） 447.87630 |
| 売上高 | 売上高（百万ドル） 174.34600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 366.46230 |
| 当期純利益 | 当期純利益（百万ドル） 25.80700 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2017 Sinovac Biotech Ltd. revenues increased from $72.4M to $174.3M. Net income before extraordinary items totaled $25.8M vs. loss of $2.9M. Revenues reflect Enterovirus 71 vaccines segment increase from $35.1M to $121.3M Inactivated hepatitis vaccines segment increase of 84% to $37.9M Hong Kong segment increase of 16% to $1.4M. |
SVAのテクニカル分析
SVAのニュース
SINOVAC DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sinovac Biotech Ltd. and Encourages Investors to Contact the Firm 2022/10/15 01:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sinovac securities between April 11, 2016 and February 22, 2019, both dates inclusive (the “Class Period”
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Sinovac Biotech Ltd. (SVA) Investors of Class Action Deadline Against 1Globe Capital LLC and to Actively Participate 2022/10/14 15:00:00 Wallstreet:Online
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against 1Globe Capital LLC (“1Globe”) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA) stock between April 11, 2016, and February 22, 2019 (the “Class
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVA 2022/10/04 22:05:00 PR Newswire
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of the stock of Sinovac Biotech Ltd. (NASDAQ: SVA) between April 11, 2016 and February 22, 2019, both dates inclusive (the "Class Period"), of the October 17, 2022 lead plaintiff…
Hong Kong reviews proposal to give children mix of BioNTech and Sinovac jabs 2022/09/21 09:06:56 South China Morning Post
Authorities confirm Post report, with health minister Lo Chung-mau and scientific committee to review application to make available BioNTech jab for youngsters.
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVA 2022/09/14 08:09:00 PR Newswire
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of the stock of Sinovac Biotech Ltd. (NASDAQ: SVA) between April 11, 2016 and February 22, 2019, both dates inclusive (the "Class Period"), of the October 17, 2022 lead…
Sinovac Biotech GAAP EPS of $74.27, revenue of $19.4B 2022/05/02 07:48:59 Seeking Alpha
Sinovac Biotech press release (SVA): FY GAAP EPS of $74.27.Revenue of $19.4B (+3699.5% Y/Y).Non-GAAP adjusted EBITDA was $17.6B in 2021, compared to $229.9M in the prior year.As…
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F 2022/04/29 22:30:00 Business Wire
BEIJING, China--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021. Second Half and Full Year 2021 Financial Summary Sales for the six months ended December 31, 2021 we
Vaccines against Omicron approved for clinical trials 2022/04/27 08:47:05 ECNS China News
Two homegrown Omicron-specific COVID-19 vaccine candidates developed by Sinopharm and Sinovac Biotech have been approved for clinical trials by China''s top drug regulator, the two companies said on Tuesday.
Sinovac Biotech''s Omicron-specific vaccine cleared for clinical trial in Hong Kong 2022/04/18 08:29:04 Seeking Alpha
Sinovac Biotech''s (SVA) Omicron-specific vaccine was approved for clinical trials in Hong Kong.Sinovac, a unit of Sinopharm Group (SHTDF) (SHTDY), said preclinical studies showed that…
Sinovac booster shows 98% protection against death/severe COVID in people over 60 in study 2022/03/24 11:08:24 Seeking Alpha
Sinovac Biotech (SVA) said a study in Hong Kong suggested that three shots of its COVID-19 vaccine CoronaVac offered ~98% protection against death or severe illness in people over 60…
Sinovac booster weaker against Omicron - HK study 2021/12/24 00:18:00 Malaysia Kini
Analysis reveals Pfizer-BioNTech vaccine more effective.
Futures Ramp Above 4,700 On Growing Omicron Optimism 2021/12/23 13:06:18 Zero Hedge
Futures Ramp Above 4,700 On Growing Omicron Optimism If you had gone to bed on Thanksgiving after eating a little too much tryptophan and only woken up today, roughly one month later, you would have completely avoided a rollercoaster move in global markets, and much of the omicron panic, with the S&P now trading precisely where it was the night before scattered reports of Omicron in South Africa sparked a global selloff. As of 730am, e-mini S&P futures were trading at exactly 4,700, up 14 points or 0.3% - and once again less than 1% from all time highs - on rising hopes the omicron variant wont impact global growth even as officials remain cautious about its spread, after studies showed its less severe than other strains; Dow Jones futures also rose 0.3% while Nasdaq 100 futures were 0.2% higher. US Treasury yields rose, the 10Y trading at 1.475%, while the USD index traded flat. The pound rose as traders stepped up bets on a Bank of England rate hike. Soaraing European natural gas prices plunged more than 20% as this years rally attracted a flotilla of U.S. cargoes, helping offset lower flows from Russia.
2.3bn Covid shots useless against Omicron study 2021/12/23 11:07:41 Russia Today
A Chinese study has revealed that the vaccine made by Chinas Sinovac Biotech fails to provide adequate protection against the Omicron variant of Covid-19 even after a booster shot has been administered. Read Full Article at RT.com
3 Sinovac shots won''t fully protect against Omicron - study 2021/12/23 10:03:00 Breaking the News 24/7
Three doses of the COVID-19 vaccine developed by Chinese company Sinovac Biotech fail to fully protect against the Omicron coronavirus variant, according to the latest study published on Thursday. Ho…